Develop and test a theoretical acceptability model for the Nestorone®/ethinyl estradiol contraceptive vaginal ring (CVR); explore whether domains of use within the model predict satisfaction, method adherence and CVR continuation.
Four domains of use were considered relative to outcome markers of acceptability, that is, method satisfaction, adherence and continuation. A questionnaire to evaluate subjects' experiences relative to the domains, their satisfaction (Likert scale) and adherence to instructions for use was developed and administered to 1036 women enrolled in a 13-cycle Phase 3 trial. Method continuation was documented from the trial database. Stepwise logistic regression (LR) analysis was conducted and odds ratios (ORs) calculated to assess associations of satisfaction with questions from the four domains. Fisher's Exact Test was used to determine the association of satisfaction with outcome measures.
A final acceptability model was developed based on the following determinants of CVR satisfaction: ease of use, side effects, expulsions/feeling the CVR and sexual activity including physical effects during intercourse. Satisfaction was high (89%) and related to higher method adherence [OR, 2.6 (1.3, 5.2)] and continuation [OR, 5.5 (3.5, 8.4)]. According to the LR analysis, attributes of CVR use representing items from the four domains — finding it easy to remove, not complaining of side effects, not feeling the CVR while wearing it and experiencing no change or an increase in sexual pleasure and/or frequency — were associated with higher odds of satisfaction.
Hypothesized domains of CVR use were related to satisfaction, which was associated with adherence and continuation. Results provide a scientific basis for introduction and future research.
Acceptability research is important when introducing a new method of contraception and determining whether it can be a successful option in meeting the reproductive health needs of women and men. This study was designed to test a conceptual model of acceptability and identify factors associated with successful use of a new contraceptive delivery modality. Original research was conducted for this publication.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Contraceptive vaginal rings releasing Nestorone and ethinyl estradiol: a 1-year dose-finding trial.Contraception. 2005; 71: 122-129
- Current status of contraceptive vaginal rings.Contraception. 2013; 87: 264-272
- Acceptability of the contraceptive vaginal ring by rural and urban populations in two Latin American countries.Contraception. 1981; 24: 393-414
- Contraceptives technologies: responding to women's needs.Guttmacher Institute, NewYork2011
- In search of breakthroughs: renewing support for contraceptive research and development.in: Guttmacher Policy Review Winter. 16 (1). 2013
- Meeting the unmet need for family planning; now is the time.Lancet. 2013; 381: 1696-1699
- User's perception of the contraceptive vaginal ring: a field study in Brazil and the Dominican Republic.Stud Fam Plan. 1983; 14: 284-290
- The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability.Contraception. 2003; 67: 187-194
- New frontiers in contraceptive research: a blueprint for action.Institute of Medicine, National Academy of Sciences, 2004: 10
- Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women.Contraception. 2013; 88: 591-598
- Women’s perceptions and experience with the progesterone vaginal ring for contraception during breastfeeding.Reprod Health Matters. 1997; : 49-57
- Westhoff C acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive.Contraception. 2006; 73: 488-492
- Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial.Obstet Gynecol. 2008; 111: 267-277
- Vaginal ring contraception.Contraception. 2011; 83: 107-115
- The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring.Contraception. 1995; 51: 39-44
- Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.Hum Reprod. 2001; 16: 463-475
- Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 micrograms of ethinyl estradiol and 3 mg of drospirenone.Contraception. 2006; 74: 451-457
- A comparison between the vaginal ring and oral contraceptives.Obstet Gynecol. 2004; 104: 555-563
- Contraceptive vaginal ring.Clin Obstet Gynecol. 2007; 50: 878-885
- Review of the vaginal contraceptive ring (NuvaRing).J Fam Plann Reprod Health Care. 2008; 34: 247-250
- Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.Contraception. 2006; 74: 220-223
- Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany.Eur J Contracept Reprod Health Care. 2008; 13: 31-38
- Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.Obstet Gynecol. 2002; 100: 585-593
- Contraceptive methods women have ever used: United States, 1982–2010.in: National Health Statistics Report. 2013 ()
- Consistency in the reporting of sexual behavior by adolescent girls in Kenya: a comparison of interviewing methods.Sex Transm Infect. 2004; 80: ii43-ii48
- Psychometric theory.McGraw Hill, Inc., USA1978
- Applied logistic regression.Wiley, New York2000
- Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use.AIDS Behav. 2012; 16: 1787-1798
- Vaginal rings for menopausal symptom relief.Drugs Aging. 2004; 21: 757-766
- State of the art intravaginal ring technology for topical prophylaxis of HIV infection.AIDS Rev. 2012; 14: 62-77
Published online: June 02, 2014
Accepted: May 27, 2014
Received in revised form: May 7, 2014
Received: December 26, 2013
☆Funding Sources: National Institute of Health/NICHD 3RO1HD047764-02S2; USAID GPO-A-00-04-00019.
☆☆Clinical Trial Registration Number: NCT00263341.
© 2014 Published by Elsevier Inc.